STEALTH BIOTHERAPEUTICS INC.

Lobbying for STEALTH BIOTHERAPEUTICS INC. · Developing therapies to treat mitochondrial dysfunction.

Filing 4th Quarter - Report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 20, 2026

Expenses

$110,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Massachusetts

Official filing document

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 6

HR 1262
Mikaela Naylon Give Kids a Chance Act
S 932
Give Kids a Chance Act of 2025
HR 1532
Scientific EXPERT Act of 2025
S 822
Scientific EXPERT Act of 2025
HR 4121
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
S 2256
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026

Lobbying activity 1

Health Issues

H.R. 1262/S. 932 - Mikaela Naylon Give Kids a Chance Act General discussions about ultra-rare diseases General discussions about ultra-rare disease drug development General discussions about regulatory reform, including scientific-focused drug development meetings General discussions about mitochondrial diseases H.R. 1532/S. 822, the Scientific EXPERT Act of 2025FDA Rare Disease Innovation Hub Fiscal Year 2026 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R. 4121 / S. 2256)

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.